View post:
ObsEva Announces Proposed Changes to the Composition of its Board of Directors

Read more:
CRISPR Therapeutics to Participate in the Guggenheim Healthcare Talks 2021 Oncology Day

See original here:
Soleno Therapeutics Provides Recap of Key Opinion Leader Webinar on DCCR for Treatment of Prader-Willi Syndrome

See the original post:
Immutep Announces Advancement Of Phase II Trial For Eftilagimod Alpha In Covid-19 Patients To Randomised Portion Of The Study

Go here to see the original:
Tiziana Life Sciences plc ("Tiziana" or the "Company") - Tiziana Files Registration Statement on Form F-3 with U.S. Securities and...

Link:
Codiak Reports Positive Initial Phase 1 Results for exoIL-12™ Demonstrating Tolerability and Absence of Systemic IL-12 Exposure in Healthy...

Visit link:
AzurRx BioPharma CEO Issues Letter to Shareholders

Here is the original post:
Kiadis issues options to newly hired employees to meet its existing obligations

Read more here:
Todos Medical Announces Positive In Vitro Data for Tollovid™ Confirming 3CL Protease Inhibition Mechanism of Action

See the rest here:
Resverlogix Files Notice of Annual and Special Meeting of Shareholders

Follow this link:
Crinetics Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update

Read more from the original source:
22nd Century Group CEO James A. Mish to Speak at Cowen 2020 Boston Cannabis Conference

Link:
Update on FDA Advisory Committee’s Meeting on Aducanumab in Alzheimer’s Disease

View original post here:
Aeterna Zentaris Reports Third Quarter 2020 Financial Results and Provides Business Update

See the original post:
Gritstone Oncology Reports Third Quarter Financial Results and Recent Highlights

Follow this link:
Arch Biopartners Announces Dosing of First Patient in Turkey in Phase II Trial of LSALT peptide to Treat Complications from Covid-19

View original post here:
Biosyent Announces Launch of New FeraMAX® Pd Therapeutic 150

Read more:
Nobilis Therapeutics to Present at CapCon 2020 Venture Conference

Continue reading here:
Cara Therapeutics to Announce Third Quarter 2020 Financial Results on November 9, 2020

Go here to see the original:
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19